Dr. Erik Yeo

Claim this profile

Toronto General Hospital

Studies Deep Vein Thrombosis
Studies Venous Thromboembolism
5 reported clinical trials
7 drugs studied

Affiliated Hospitals

Image of trial facility.

Toronto General Hospital

Image of trial facility.

UHN Toronto General Hospital

Clinical Trials Erik Yeo is currently running

Image of trial facility.

Statins

for Blood Clots

The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants). While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming. The medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study. The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.

Recruiting

1 award

Phase 3

1 criteria

Image of trial facility.

Cancer Screening

for Blood Clots

This trial is testing if using a special imaging test called FDG-PET/CT can better detect hidden cancers in patients who have had their first unprovoked blood clot. The test works by using a sugary dye that cancer cells absorb, making them visible on the scan. The goal is to see if this method finds more hidden cancers compared to standard screening.

Recruiting

1 award

N/A

6 criteria

More about Erik Yeo

Clinical Trial Related

8 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Erik Yeo has experience with

  • Apixaban
  • Abelacimab
  • Rivaroxaban
  • Limited Cancer Screening
  • Limited Cancer Screening + FDG PET/CT
  • Placebo Oral Tablet

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Erik Yeo specialize in?

Is Erik Yeo currently recruiting for clinical trials?

Are there any treatments that Erik Yeo has studied deeply?

What is the best way to schedule an appointment with Erik Yeo?

What is the office address of Erik Yeo?

Is there any support for travel costs?